Medicare should continue to pay average sales price plus 6% for most separately payable Part B drugs, but cap ASP inflation, AHA told the Medicare Payment Advisory Commission in comments submitted today. 

At its January meeting, MedPAC discussed modifying the ASP add-on payment to the lesser of 6%, 3% plus $24, or $220 per drug per day; and using reference pricing to address high prices and price growth for new and existing drugs with therapeutic alternatives. AHA expressed concern that both proposals would shift responsibility for rapid growth in drug prices from drug makers to hospitals and patients.

Among other comments, AHA recommended Medicare permanently extend certain telehealth flexibilities used to expand access to care during the COVID-19 pandemic and reconsider certain other policy options that run contrary to what these permanent extensions would accomplish.
 

Related News Articles

Headline
Over 30 organizations, including the AHA, urged Congress to swiftly pass the Saving Access to Laboratory Services Act (S. 1000/H.R. 2377), bipartisan…
Headline
As the House Energy and Commerce Committee prepares to consider a legislative provision (H.R. 3561) that would reduce payments for drug administration services…
Headline
AHA May 17 shared with the Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations its concern that some MA plans inappropriately…
Headline
The Centers for Medicare and Medicare Services announced plans to start an AHA-opposed demonstration for inpatient rehabilitation facilities Aug. 21…
Headline
A bipartisan group of over 230 representatives urged House leaders to prevent $8 billion in cuts to Medicaid Disproportionate Share Hospital payments scheduled…
Headline
AHA this week joined 30 other organizations in voicing support for the Chronic Care Management Improvement Act, legislation that would remove the 20% cost-…